Crossmark

Will 68 Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update

Crossref DOI link: https://doi.org/10.1016/j.remnie.2017.10.029

Published Print: 2018-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cuccurullo, Vincenzo

Di Stasio, Giuseppe Danilo

Evangelista, Laura

Ciarmiello, Andrea

Mansi, Luigi
License Information

Text and Data Mining valid from 2018-03-01
More Information

This article is maintained by: Elsevier

Article Title: Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update

Journal Title: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.remnie.2017.10.029

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.remn.2017.10.008

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. and SEMNIM. All rights reserved.